AVON, Conn.--(BUSINESS WIRE)--As the pipeline of oncology and medical injectables continues to grow, health care payors are increasingly concerned about the clinical management and cost of these drugs, which are paid under the medical benefit rather than the pharmacy benefit. Taking proactive steps to manage these costs, payors are turning their attention to the settings in which the injectables are administered, and seeking data to guide their reimbursement strategies. Today, Magellan Health Services (NASDAQ: MGLN) released its second annual Medical Pharmacy & Oncology Trend Report from ICORE, a unit within the company’s recently combined Magellan Pharmacy Solutions division. The report is the only industry benchmark of its kind to effectively analyze both medical and pharmacy data to explain the trends surrounding specialty drugs such as those used to treat complex chronic conditions such as cancer, rheumatoid arthritis and multiple sclerosis.
